Epistaxis medical therapy: Difference between revisions
Amir Bagheri (talk | contribs) No edit summary |
Amir Bagheri (talk | contribs) No edit summary |
||
Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Most of the time no action is needed to stop epistaxis. In active bleeding nasal compression is the first line to stop bleeding. If bleeding continues there are other options like cautery and some vasoconstrictive agents like [[oxymetazoline]] or [[phenylephrine]] to control bleeding. | Most of the time no action is needed to stop [[epistaxis]]. In active [[bleeding]] nasal compression is the first line to stop bleeding. If [[bleeding]] continues there are other options like [[cautery]] and some [[vasoconstrictive]] agents like [[oxymetazoline]] or [[phenylephrine]] to control [[bleeding]]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
Line 19: | Line 19: | ||
*'''[[Vasoconstrictors]]''' (Use with caution in children and patients with [[glaucoma]], [[Hypertension|HTN]], [[peripheral vasoconstriction]], [[Cardiac disease|cardiac diseases]] and [[cerebrovascular]] problems): | *'''[[Vasoconstrictors]]''' (Use with caution in children and patients with [[glaucoma]], [[Hypertension|HTN]], [[peripheral vasoconstriction]], [[Cardiac disease|cardiac diseases]] and [[cerebrovascular]] problems): | ||
**Preferred regimen (1): [[Oxymetazoline]] 0.05% [[intranasal]] [[spray]]. In children <6 years just with [[physicians]] suggestion. | **Preferred regimen (1): [[Oxymetazoline]] 0.05% [[intranasal]] [[spray]]. In children <6 years just with [[physicians]] suggestion. | ||
**Alternative regimen (1): [[Phenylephrine]] 0.25% [[intranasal spray]]. In children ≥2 years Phenylephrine 0.125% nasal solution can be used. | **Alternative regimen (1): [[Phenylephrine]] 0.25% [[intranasal spray]]. In children ≥2 years [[Phenylephrine]] 0.125% nasal solution can be used. | ||
**Alternative regimen (2): [[Epinephrine]] 1:100,000 with [[Lidocaine]] 1% (Topical ). | **Alternative regimen (2): [[Epinephrine]] 1:100,000 with [[Lidocaine]] 1% ([[Topical]] ). | ||
*'''[[Antifibrinolytic]]''': | *'''[[Antifibrinolytic]]''': | ||
**Preferred regimen (1): [[Tranexamic acid]] ([[Tranexamic acid|TXA]]) (Topical ).<br /> | **Preferred regimen (1): [[Tranexamic acid]] ([[Tranexamic acid|TXA]]) ([[Topical]] ).<br /> | ||
*'''[[Chemical]] [[cauterization]]''' ( At first [[anesthesia]] [[bleeding]] site and limit nasal [[cautery]] to site''':''' | *'''[[Chemical]] [[cauterization]]''' ( At first [[anesthesia]] [[bleeding]] site and limit nasal [[cautery]] to site''':''' |
Revision as of 21:05, 27 October 2020
Epistaxis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Epistaxis medical therapy On the Web |
American Roentgen Ray Society Images of Epistaxis medical therapy |
Risk calculators and risk factors for Epistaxis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:Amir Behzad Bagheri, M.D.
Overview
Most of the time no action is needed to stop epistaxis. In active bleeding nasal compression is the first line to stop bleeding. If bleeding continues there are other options like cautery and some vasoconstrictive agents like oxymetazoline or phenylephrine to control bleeding.
Medical Therapy
If nasal bleeding is active and nasal compression couldn't stop bleeding, there are the following medical options:[1] [2] [3] [4] [5]
General management of patients is important. Stabilizing the patient and treating the specific cause is the basis of management.
At first airway , breathing and circulation should be evaluated.
Medical Therapy:
- Vasoconstrictors (Use with caution in children and patients with glaucoma, HTN, peripheral vasoconstriction, cardiac diseases and cerebrovascular problems):
- Preferred regimen (1): Oxymetazoline 0.05% intranasal spray. In children <6 years just with physicians suggestion.
- Alternative regimen (1): Phenylephrine 0.25% intranasal spray. In children ≥2 years Phenylephrine 0.125% nasal solution can be used.
- Alternative regimen (2): Epinephrine 1:100,000 with Lidocaine 1% (Topical ).
- Antifibrinolytic:
- Preferred regimen (1): Tranexamic acid (TXA) (Topical ).
- Preferred regimen (1): Tranexamic acid (TXA) (Topical ).
- Chemical cauterization ( At first anesthesia bleeding site and limit nasal cautery to site:
- Preferred regimen (1): Silver nitrate 25%-75%
- Alternative regimen (1): Chromic acid
- Alternative regimen (2): Trichloroacetic acid
References
- ↑ Tunkel, David E.; Anne, Samantha; Payne, Spencer C.; Ishman, Stacey L.; Rosenfeld, Richard M.; Abramson, Peter J.; Alikhaani, Jacqueline D.; Benoit, Margo McKenna; Bercovitz, Rachel S.; Brown, Michael D.; Chernobilsky, Boris; Feldstein, David A.; Hackell, Jesse M.; Holbrook, Eric H.; Holdsworth, Sarah M.; Lin, Kenneth W.; Lind, Meredith Merz; Poetker, David M.; Riley, Charles A.; Schneider, John S.; Seidman, Michael D.; Vadlamudi, Venu; Valdez, Tulio A.; Nnacheta, Lorraine C.; Monjur, Taskin M. (2020). "Clinical Practice Guideline: Nosebleed (Epistaxis)". Otolaryngology–Head and Neck Surgery. 162 (1_suppl): S1–S38. doi:10.1177/0194599819890327. ISSN 0194-5998.
- ↑ Krempl, Greg A.; Noorily, Allen D. (2016). "Use of Oxymetazoline in the Management of Epistaxis". Annals of Otology, Rhinology & Laryngology. 104 (9): 704–706. doi:10.1177/000348949510400906. ISSN 0003-4894.
- ↑ Montastruc, François; Montastruc, Guillaume; Taudou, Marie-Josée; Olivier-Abbal, Pascale; Montastruc, Jean-Louis; Bondon-Guitton, Emmanuelle (2014). "Acute Coronary Syndrome After Nasal Spray of Oxymetazoline". Chest. 146 (6): e214–e215. doi:10.1378/chest.14-1873. ISSN 0012-3692.
- ↑ Krulewitz, Neil Alexander; Fix, Megan Leigh (2019). "Epistaxis". Emergency Medicine Clinics of North America. 37 (1): 29–39. doi:10.1016/j.emc.2018.09.005. ISSN 0733-8627.
- ↑ Douglas, Richard; Wormald, Peter-John (2007). "Update on epistaxis". Current Opinion in Otolaryngology & Head and Neck Surgery. 15 (3): 180–183. doi:10.1097/MOO.0b013e32814b06ed. ISSN 1068-9508.